ENTITY
Merck & Co

Merck & Co (MRK US)

211
Analysis
Health CareUnited States
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
more
08 Jan 2025 22:12Issuer-paid

Biopharma Week in Review - January 6, 2025

On the obesity front, NVO’s CagriSema fell short of expectations, while the FDA reaffirmed LLY’s GLP-1 shortage resolution, bearing bad news for...

Logo
185 Views
Share
18 Dec 2024 20:51Issuer-paid

Biopharma Week in Review - December 16, 2024

LLY partnered GLP-1 access with telehealth Ro and presented oral SERD data in breast cancer, rattling HIMS, LFMD, ARVN, and OLMA.

Logo
185 Views
Share
19 Nov 2024 06:24Issuer-paid

Biopharma Week in Review - November 18, 2024

ABBV’s costly neuro play failed, removing the main threat to BMY’s Cobenfy. AMGN was rattled by bone loss data for its obesity drug.

Logo
164 Views
Share
17 Sep 2024 06:44Issuer-paid

Biopharma Week in Review - September 16, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.

Logo
232 Views
Share
09 Jul 2024 06:03Issuer-paid

Biopharma Week in Review - Jul 8, 2024

The cost of Kisunla is $32K/year, which is at a premium to Leqembi (Biogen, Inc. [BIIB]/Eisai Co., Ltd. [ESAIY]) at $26.5K/year, but total cost per...

Logo
186 Views
Share
x